No Data
No Data
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12